mitoxantrone

P3, N=1186, Recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2029 | Trial primary completion date: Sep 2027 --> Jun 2029

This study identifies the Rac1-USP11 reciprocal feedback loop as a novel, self-reinforcing mechanism driving radioresistance in HCC. Targeting this loop via combined Rac1-GTP/USP11 inhibition represents a promising therapeutic strategy for radiosensitizing HCC.

Our results suggest that an interplay of both canonical and non-canonical MX-antitumor activity overwhelms the BRCA1- UWB1.289 cells. Furthermore, this study characterizes the target landscape of MX, providing insights into off-target effects and MX action in HR-deficient cancer.

Not available.

P2, N=240, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting

P2, N=22, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2030 --> Sep 2029

P2, N=240, Recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2026 --> Dec 2027

We therefore measured global chromatin accessibility across iPSC-derived cardiomyocytes derived from four healthy individuals that we treated with topoisomerase II (TOP2) inhibiting ACs, Doxorubicin, Epirubicin, and Daunorubicin, and the anthracenedione, Mitoxantrone as well as the TOP2-independent monoclonal antibody Trastuzumab, for three and 24 hours. Our results demonstrate large-scale changes in chromatin accessibility in cardiomyocytes treated with ACs, which correspond to several regions harboring AF and HF risk loci. The identified drug-responsive chromatin regions can be used to annotate variants in cancer patient populations to contribute to risk estimation for CVD.

P2, N=22, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

Mitoxantrone, a promising inducer, is encapsulated in platelet membrane-hybridized liposomes to enhance targeted delivery and therapeutic efficacy...This activated Caspase8 and the NLRP3 inflammasome, leading to GSDMC cleavage and initiating pyroptosis. Collectively, this study provides an innovative pyroptosis therapy strategy combining physical treatment and chemotherapy for BLBC and other refractory diseases.

Collectively, our finding indicate that the miR-183-5p/STC1 axis modulates MIT's cytotoxicity through targeted regulation and a negative feedback mechanisms, thereby influencing HCC cell proliferation, apoptosis, and ICD. These insights offer noval strategies for synergistic therapy that integrate epigenetics and the immune microenvironment in HCC treatment.